BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 59.08% | 63.65% | 154.10% | 57.96% | -198.67% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.62% | -98.89% | -1,126.66% | -71.10% | 1,753.15% |
| Change in Net Operating Assets | -174.28% | 145.53% | -38.47% | 165.89% | -9.66% |
| Cash from Operations | -1,591.01% | 38.73% | 100.76% | 99.05% | 69.78% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 7.67% | 289.60% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 2.49% | 288.98% | -100.00% | -- |
| Foreign Exchange rate Adjustments | 96.88% | 100.00% | -600.00% | 115.08% | -420.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,251.43% | -1,766.35% | 1,470.63% | -99.48% | 63.73% |
